SCI时时刷

search
+
Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer
Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer
Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immun...
A fishnet between nasopharyngeal carcinoma and resistance: the competing endogenous RNA network
A fishnet between nasopharyngeal carcinoma and resistance: the competing endogenous RNA network
Chemotherapy and radiotherapy (chemo-/radiotherapy) have advanced as the main treatment modalities for nasopharyngeal carc...
Central Nervous System Metastases in Breast Cancer
Central Nervous System Metastases in Breast Cancer
Breast cancer metastasizing to the central nervous system (CNS) encompasses two distinct entities: brain metastases involv...
A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective
A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective
Integrating clinical datasets in breast cancer research emerges as a necessary tool for advancing our knowledge of the dis...
Treatment Options for IDH-Mutant Malignant Gliomas
Treatment Options for IDH-Mutant Malignant Gliomas
As the peak incidence of isocitrate dehydrogenase (IDH)-mutant gliomas is amongst young adults, there is a need to balance...
A Review of Current and Future Antibody Drug Conjugates in Breast Cancer
A Review of Current and Future Antibody Drug Conjugates in Breast Cancer
Antibody–drug conjugates (ADCs) are a novel class of anti-cancer agents that have changed the standard of care for p...
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review
Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) have revolutionized the management of hormone receptor-positive (HR&...
From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer
From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer
The biological heterogeneity of colorectal cancer makes its molecular characteristics essential for therapeutic decision-m...
Molecular Secrets Revealed: How Diabetes may be Paving the Way for Leukemia
Molecular Secrets Revealed: How Diabetes may be Paving the Way for Leukemia
Type 2 Diabetes Mellitus (T2DM) and leukemia are two major global health concerns, both contributing significantly to morb...
“When Less is More”: Paradigm Shifts in Radiation Treatment for Early-Stage Breast Cancer
“When Less is More”: Paradigm Shifts in Radiation Treatment for Early-Stage Breast Cancer
Recent advancements in the treatment of early-stage breast cancer have significantly shifted the radiotherapy landscape. T...
New Therapeutic Targets in RAS Wild-type Pancreatic Cancer
New Therapeutic Targets in RAS Wild-type Pancreatic Cancer
The landscape of treatment of advanced PDAC is witnessing significant changes. This is in part due to the advent of molecu...
Updates in Treatment of HER2-positive Metastatic Breast Cancer
Updates in Treatment of HER2-positive Metastatic Breast Cancer
The therapeutic landscape for HER2-positive metastatic breast cancer has exploded in the last two decades following the in...
An Update on the Management of Rectal Neuroendocrine Neoplasms
An Update on the Management of Rectal Neuroendocrine Neoplasms
Rectal neuroendocrine neoplasms (NENs) are increasing in incidence. Most lesions are low grade, well-differentiated neuroe...
Immunotherapy in the Fight Against Bone Metastases: A Review of Recent Developments and Challenges
Immunotherapy in the Fight Against Bone Metastases: A Review of Recent Developments and Challenges
Bone metastasis, a frequent and detrimental complication of advanced cancers, often triggers bone deterioration events tha...
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update
Gastrointestinal stromal tumor (GIST) is characterized by well-defined oncogenes. Despite the significant improvement in t...
Targeting the Renin–angiotensin–aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review
Targeting the Renin–angiotensin–aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review
The renin–angiotensin–aldosterone system (RAAS) is a crucial regulator of the cardiovascular system and a targ...
Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy
Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy
Multiple myeloma (MM) is a heterogeneous plasma cell tumor with a survival period of several months to over ten years. Des...
Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia
Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia
Mutations in isocitrate dehydrogenase-1 (IDH1) are recurrent in several malignancies and prevalent in acute myeloid leukem...
Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer
Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer
Lung cancer is expected to contribute to about 0.234 million new cases and about 0.125 million mortalities in the United S...
The Role of SIRT1 in Leukemia
The Role of SIRT1 in Leukemia
Leukemia is a type of hematological malignancy (HM) caused by uncontrolled proliferation, apoptosis, and differentiation o...
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer
Recommended first and second line treatments for unresectable metastatic colorectal cancer (mCRC) include fluorouracil-bas...
Research Progress on Ferroptosis in Multiple Myeloma
Research Progress on Ferroptosis in Multiple Myeloma
Multiple myeloma (MM) is the second most common hematological malignant (HM) tumor, and a large proportion of patients sti...
Myeloproliferative Neoplasms and Cardiovascular Disease: A Review
Myeloproliferative Neoplasms and Cardiovascular Disease: A Review
Myeloproliferative neoplasms (MPN) are a heterogenous group of disorders of clonal hematopoiesis characterized by constitu...
The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy
The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy
Hepatocellular carcinoma (HCC) is a common type of tumor worldwide. The development of systemic treatment of advanced HCC ...
Gastrointestinal Cancer Therapy and Cardiotoxicity
Gastrointestinal Cancer Therapy and Cardiotoxicity
Gastrointestinal cancers are a heterogenous group of cancers that share common risk factors with cardiovascular disease. T...
Advancements in Melanoma Therapies: From Surgery to Immunotherapy
Advancements in Melanoma Therapies: From Surgery to Immunotherapy
Melanoma is defined as the most aggressive and deadly form of skin cancer. The treatment of melanoma depends on the&nb...
Management Approaches for High-Risk Cutaneous Squamous Cell Carcinoma with Perineural Invasion: An Updated Review
Management Approaches for High-Risk Cutaneous Squamous Cell Carcinoma with Perineural Invasion: An Updated Review
Cutaneous squamous cell carcinoma (cSCC) stands as the second most prevalent non-melanoma skin cancer worldwide, comprisin...
Small Cell Lung Cancer—An Update on Chemotherapy Resistance
Small Cell Lung Cancer—An Update on Chemotherapy Resistance
Compared to other types of lung cancer, small cell lung cancer (SCLC) exhibits aggressive characteristics that promote dru...
Opportunities and Challenges in Soft Tissue Sarcoma Risk Stratification in the Era of Personalised Medicine
Opportunities and Challenges in Soft Tissue Sarcoma Risk Stratification in the Era of Personalised Medicine
Soft tissue sarcomas (STS) are a rare and heterogeneous group of cancers. Treatment options have changed little in the pas...
Modern Management of Gastric Neuroendocrine Neoplasms
Modern Management of Gastric Neuroendocrine Neoplasms
Gastric neuroendocrine neoplasms (G-NENs) are a heterogeneous group of tumors that broadly fall into two groups. The first...
阅读更多
format_indent_increase